specificity of binding as that antibody defined in claim 4.

B2 6. (Twice Amended) The pharmaceutical composition of claim 1, wherein two or more antibodies, which are directed against different membrane antigens or against different epitopes of a membrane antigen, are used in combination with each other.

Please add the following claims:

10. (New) A pharmaceutical composition for therapeutic vaccination against cancer comprising at least one monoclonal antibody of animal origin directed against the cellular membrane antigen Ep-CAM, wherein one of said at least one antibody has the amino acid sequence of SEQ ID NO:1 for the variable region of the heavy chain and the amino acid sequence of SEQ ID NO:2 for the variable region of the light chain.

B3

11. (New) The pharmaceutical composition of claim 10, further comprising at least one vaccine adjuvant.

12. (New) A method of therapeutic vaccination against cancer comprising administering to a patient in need thereof

the pharmaceutical composition of claim 10 at a dosage in the range of 0.01 to 4 mg antibody.

13. (New) The method according to claim 12, wherein said pharmaceutical composition is administered by subcutaneous, intradermal or intramuscular injection.

B3

14. (New) A method of vaccination against cancer comprising administering to a patient in need thereof the pharmaceutical composition of claim 1 at a dosage in the range of 0.01 to 4 mg antibody for the prevention of the development of metastasis and treatment of cancer disease.

REMARKS

Claim 1 has been amended to indicate that the composition is used to actively immunize cancer patients for the prevention of the development of metastasis in treatment of cancer disease. Support for this amendment can be found in the Specification on page 5, line 31 to page 6, line 16. Support for the amendment to claim 6 can be found on page 4, lines 13-21 and on page 5, lines 19-24. New claims 10-13 find their support in the disclosure of the existing claims and on page 6, lines 17-25.